Atalanta Therapeutics Revenue and Competitors

Boston, MA USA

Location

$110M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Atalanta Therapeutics's estimated annual revenue is currently $13M per year.(i)
  • Atalanta Therapeutics's estimated revenue per employee is $155,000
  • Atalanta Therapeutics's total funding is $110M.

Employee Data

  • Atalanta Therapeutics has 84 Employees.(i)
  • Atalanta Therapeutics grew their employee count by 18% last year.

Atalanta Therapeutics's People

NameTitleEmail/Phone
1
General CounselReveal Email/Phone
2
SVPReveal Email/Phone
3
Laboratory Operations ManagerReveal Email/Phone
4
Senior Director, ControllerReveal Email/Phone
5
Sr. Director, ResearchReveal Email/Phone
6
Chief Scientific OfficerReveal Email/Phone
7
Senior ScientistReveal Email/Phone
8
VP, Head in vivo PharmacologyReveal Email/Phone
9
Chief Corporate Development OfficerReveal Email/Phone
10
Scientist, Neuroscience BiologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Atalanta Therapeutics?

We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.

keywords:N/A

$110M

Total Funding

84

Number of Employees

$13M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Atalanta Therapeutics News

2022-03-22 - Atalanta Therapeutics Appoints Alfred Sandrock to Board of Directors Business Wire

Atalanta Therapeutics Appoints Alfred Sandrock to Board of Directors Business Wire

2021-01-11 - Atalanta Therapeutics Raises $110M in Series A Funding

Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (N ...

2021-01-11 - Atalanta Therapeutics Raises $110M in Series A Funding

Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (N ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21M8422%N/A
#2
$10.9M84-38%$32M
#3
$15M841%N/A
#4
$27.1M84-20%N/A
#5
$12.2M84-36%$67.4M